Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine
This double-blind, placebo-controlled crossover study in 28 healthy volunteers found that LSD, d‑amphetamine and MDMA all reduced within‑network (integrity) connectivity but produced distinct large‑scale connectivity signatures. LSD uniquely decreased default‑mode network integrity, drove stronger between‑network increases and segregation decreases and increased global connectivity in basal ganglia and thalamus, whereas the amphetamines reduced integrity across more networks and produced both increases and decreases in segregation.
Authors
- Patrick Vizeli
- Stefan Borgwardt
- Felix Müller
Published
Abstract
Psychedelics have recently attracted significant attention for their potential to mitigate symptoms associated with various psychiatric disorders. However, the precise neurobiological mechanisms responsible for these effects remain incompletely understood. A valuable approach to gaining insights into the specific mechanisms of action involves comparing psychedelics with substances that have partially overlapping neurophysiological effects, i.e., modulating the same neurotransmitter systems. Imaging data were obtained from the clinical trial NCT03019822, which explored the acute effects of lysergic acid diethylamide (LSD), d-amphetamine, and 3,4-methylenedioxymethamphetamine (MDMA) in 28 healthy volunteers. The clinical trial employed a double-blind, placebo-controlled, crossover design. Herein, various resting-state connectivity measures were examined, including within-network connectivity (integrity), between-network connectivity (segregation), seed-based connectivity of resting-state networks, and global connectivity. Differences between placebo and the active conditions were assessed using repeated-measures ANOVA, followed by post-hoc pairwise t-tests. Changes in voxel-wise seed-based connectivity were correlated with serotonin 2 A receptor density maps. Compared to placebo, all substances reduced integrity in several networks, indicating both common and unique effects. While LSD uniquely reduced integrity in the default-mode network (DMN), the amphetamines, in contrast to our expectations, reduced integrity in more networks than LSD. However, LSD exhibited more pronounced segregation effects, characterized solely by decreases, in contrast to the amphetamines, which also induced increases. Across all substances, seed-based connectivity mostly increased between networks, with LSD demonstrating more pronounced effects than both amphetamines. Finally, while all substances decreased global connectivity in visual areas, compared to placebo, LSD specifically increased global connectivity in the basal ganglia and thalamus. These findings advance our understanding of the distinctive neurobiological effects of psychedelics, prompting further exploration of their therapeutic potential.
Research Summary of 'Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine'
Introduction
Psychedelic compounds such as LSD, psilocybin and DMT have shown promise for ameliorating symptoms across a range of psychiatric disorders, but the neurobiological mechanisms that underlie their effects remain incompletely characterised. Comparing a classic serotonergic psychedelic with other psychoactive substances that share some pharmacological actions may help disentangle which connectivity changes are specific to psychedelics and which reflect more general drug effects. Resting-state functional MRI (rs-fMRI) offers a way to probe large-scale functional connectivity, including measures of within-network connectivity (integrity), between-network connectivity (segregation), seed-based whole-brain coupling of canonical resting-state networks (RSNs), and global connectivity as indexed by degree centrality (DC). Avram and colleagues set out to compare acute brain connectivity changes induced by lysergic acid diethylamide (LSD), d-amphetamine and MDMA in healthy volunteers. The primary aims were to (1) test drug effects on RSN integrity and segregation using a canonical RSN parcellation, (2) map voxel-wise whole-brain coupling of each RSN via seed-based analyses, and (3) assess changes in global connectivity with DC. The investigators also examined whether voxel-wise iFC changes related spatially to 5-HT2A receptor density from a reference atlas and whether connectivity alterations correlated with subjective effects measured by the 11D-ASC questionnaire.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Avram, M., Fortea, L., Wollner, L., Coenen, R., Korda, A., Rogg, H., Holze, F., Vizeli, P., Ley, L., Radua, J., Müller, F., Liechti, M. E., & Borgwardt, S. (2025). Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine. Molecular Psychiatry, 30(4), 1297-1307. https://doi.org/10.1038/s41380-024-02734-y
References (32)
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Holze, F., Vizeli, P., Müller, F. et al. · Neuropsychopharmacology (2019)
Molla, H. M., Lee, R., Lyubomirsky, S. et al. · Scientific Reports (2023)
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Avram, M., Müller, F., Rogg, H. et al. · Biological Psychiatry (2022)
Avram, M., Müller, F., Preller, K. H. et al. · Biological Psychiatry (2024)
Holze, F., Dolder, P. C., Ley, L. et al. · Neuropsychopharmacology (2020)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Show all 32 referencesShow fewer
Müller, F., Dolder, P. C., Schmidt, A. et al. · NeuroImage (2018)
Madsen, M. K., Stenbaek, D. S., Arvidsson, A. et al. · European Neuropsychopharmacology (2021)
Luppi, A. I., Carhart-Harris, R. L., Roseman, L. et al. · NeuroImage (2021)
Timmermann, C., Roseman, L., Haridas, S. et al. · PNAS (2023)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)
Lenz, C., Dolder, P. C., Lang, U. E. et al. · Acta Psychiatrica Scandinavica (2017)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Gattuso, J. J., Perkins, D., Ruffell, S. G. D. et al. · International Journal of Neuropsychopharmacology (2022)
Barrett, F. S., Griffiths, R. R. · Current Topics in Behavioral Neurosciences (2017)
Daws, R. E., Timmermann, C., Giribaldi, B. et al. · Nature Medicine (2022)
Nutt, D. J., Erritzoe, D., Carhart-Harris, R. L. · Cell (2020)
Singleton, S. P., Luppi, A. I., Carhart-Harris, R. L. et al. · Nature Communications (2022)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Avram, M., Rogg, H., Korda, A. et al. · Frontiers in Psychiatry (2021)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Moliner, R., Girych, M., Brunello, C. A. et al. · Nature Neuroscience (2023)
Raison, C. L., Sanacora, G., Woolley, J. D. et al. · JAMA (2023)
Cited By (3)
Papers in Blossom that reference this study
Ramaekers, J. G., Kuypers, K. P. C., Vollenweider, F. X. · Molecular Psychiatry (2026)
Egger, K., Meling, D., Polat, F. et al. · Imaging Neuroscience (2025)
McCulloch, D. E-W., Larsen, K., Johansen, A. et al. · MedRvix (2025)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.